The migraine treatment market size has grown strongly in recent years. It will grow from $3.18 billion in 2024 to $3.48 billion in 2025 at a compound annual growth rate (CAGR) of 9.4%. The growth in the historic period can be attributed to increased prevalence of migraines, increased healthcare expenditure, improved formulations of existing drugs, expansion of clinical research, development of novel therapies.
The migraine treatment market size is expected to see rapid growth in the next few years. It will grow to $5.32 billion in 2029 at a compound annual growth rate (CAGR) of 11.2%. The growth in the forecast period can be attributed to growing awareness and education, emergence of monoclonal antibodies, increasing focus on pediatric migraines, expansion of non-pharmacological interventions, global initiatives for migraine research. Major trends in the forecast period include advancements in therapeutic approaches, wearable devices and digital therapeutics, telemedicine and remote consultations, patient-centric care models, generic drug market growth, oral CGRP inhibitors.
The increase in prolonged screen exposure is anticipated to drive the growth of the migraine treatment market. Screen exposure refers to the duration individuals spend engaging with electronic screens, including those on smartphones, tablets, computers, and televisions. Factors contributing to prolonged screen exposure include the rise in remote work, online education, digital entertainment, and a greater reliance on technology for social interactions. Migraine treatments address symptoms that are triggered or exacerbated by extended screen time, encompassing medications, lifestyle changes, and ergonomic practices aimed at reducing strain and preventing attacks. For example, in May 2024, the House of Commons Committee, a health agency within the UK Parliament, reported that children's screen time surged by 52% in 2021, with nearly 25% of children and young people displaying smartphone usage patterns indicative of behavioral addiction. As a result, prolonged screen exposure is driving the growth of the migraine treatment market.
The escalating number of clinical trials stands as a catalyst for the migraine treatment market's expansion. These trials, involving human participants, aim to evaluate the safety and effectiveness of new medical interventions for migraines. They offer insights into personalized treatment strategies and potentially more efficient therapies. As per Xtalks in May 2023, there were 452,604 registered clinical studies on ClinicalTrials.gov, with 64,838 actively seeking participants - a significant increase from 2021's 365,000 registered trials. This surge in clinical trials actively contributes to the burgeoning migraine treatment market.
Product innovations are a prominent trend gaining traction in the migraine treatment market. Leading companies in the sector are introducing novel solutions, such as liquid formulations, to maintain their competitive edge. For example, in January 2022, BioDelivery Sciences International (BDSI), a US-based pharmaceutical firm, launched Elyxyb (celecoxib oral solution), designed for the acute treatment of migraines in adults, regardless of whether they experience aura. This liquid formulation facilitates rapid absorption in the small intestine, resulting in quicker relief compared to conventional tablets. This innovation is particularly advantageous for migraine sufferers who experience nausea or vomiting, as it eliminates the waiting time for a pill to dissolve. As the first and only FDA-approved ready-to-use oral solution for migraines, Elyxyb offers a more tolerable and efficient treatment option for managing the sudden, intense pain associated with migraines.
Major players in the migraine treatment market prioritize product approvals, such as the zavzpret (zavegepant) migraine nasal spray, to bolster market revenues. Zavzpret, a calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray, targets the acute management of adult migraines. Notably, Pfizer Inc. received FDA approval for zavzpret (zavegepant) in March 2023. This nasal spray offers immediate relief for adult migraine attacks, aiming to provide pain relief with a single spray. The FDA's endorsement marks a significant milestone for migraine sufferers seeking alternatives to oral medications for prompt pain relief.
In May 2022, Pfizer Inc., a prominent biopharmaceutical company based in the US, successfully completed the acquisition of Biohaven Pharmaceutical Holding Company Ltd. for an estimated $11.6 billion. This strategic acquisition positions Pfizer to further its commitment in providing effective treatments for individuals worldwide afflicted by migraines. Biohaven Pharmaceutical Holding Company Ltd., also based in the US, possesses a diverse product portfolio focused on addressing neuropsychiatric diseases and neurological disorders.
Major companies operating in the migraine treatment market are Pfizer Inc., Eli Lilly and Company, Amgen Inc., GlaxoSmithKline PLC, Novartis AG, Bayer AG, Allergan PLC, Abbott Laboratories, Allodynic Therapeutics LLC, AOBiome LLC, AstraZeneca PLC, Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, Dr. Reddy's Laboratories Limited, Impel Pharmaceuticals Inc., AbbVie Inc., Alder BioPharmaceuticals Inc., Astellas Pharma Inc., Biohaven Pharmaceutical Holding Company Ltd., Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Endo International PLC, Impax Laboratories Inc., Johnson & Johnson Inc., Lannett Company Inc., Lupin Limited, Merck & Co. Inc., Mylan N.V.
North America was the largest region in the migraine treatment market in 2024. The regions covered in the migraine treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the migraine treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Migraines, a neurological condition, are characterized by severe headaches typically felt on one side of the brain. These pulsating headaches are the primary symptom of this condition. Migraine treatment aims to alleviate these intense and often debilitating headaches by targeting the brain's pain pathways. By effectively blocking these pathways, the treatment can halt future migraine attacks and alleviate associated symptoms.
Different types of migraine treatments cater to varying migraine presentations. Episodic migraine treatment addresses instances where individuals experience headaches for 0-14 days per month. This form of treatment encompasses various acute options tailored specifically for episodic migraines. Available treatments include acute/abortive methods, preventive/prophylactic approaches, as well as non-pharmacological therapies and devices. These treatments find applications across diverse settings, including hospitals, clinics, homecare, and other end-user environments.
The migraine treatment market research report is one of a series of new reports that provides migraine treatment market statistics, including migraine treatment industry global market size, regional shares, competitors with a migraine treatment market share, detailed migraine treatment market segments, market trends and opportunities, and any further data you may need to thrive in the migraine treatment industry. This migraine treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The migraine treatment market includes revenues earned by entities by providing branded and generic migraine treatment services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The migraine treatment market size is expected to see rapid growth in the next few years. It will grow to $5.32 billion in 2029 at a compound annual growth rate (CAGR) of 11.2%. The growth in the forecast period can be attributed to growing awareness and education, emergence of monoclonal antibodies, increasing focus on pediatric migraines, expansion of non-pharmacological interventions, global initiatives for migraine research. Major trends in the forecast period include advancements in therapeutic approaches, wearable devices and digital therapeutics, telemedicine and remote consultations, patient-centric care models, generic drug market growth, oral CGRP inhibitors.
The increase in prolonged screen exposure is anticipated to drive the growth of the migraine treatment market. Screen exposure refers to the duration individuals spend engaging with electronic screens, including those on smartphones, tablets, computers, and televisions. Factors contributing to prolonged screen exposure include the rise in remote work, online education, digital entertainment, and a greater reliance on technology for social interactions. Migraine treatments address symptoms that are triggered or exacerbated by extended screen time, encompassing medications, lifestyle changes, and ergonomic practices aimed at reducing strain and preventing attacks. For example, in May 2024, the House of Commons Committee, a health agency within the UK Parliament, reported that children's screen time surged by 52% in 2021, with nearly 25% of children and young people displaying smartphone usage patterns indicative of behavioral addiction. As a result, prolonged screen exposure is driving the growth of the migraine treatment market.
The escalating number of clinical trials stands as a catalyst for the migraine treatment market's expansion. These trials, involving human participants, aim to evaluate the safety and effectiveness of new medical interventions for migraines. They offer insights into personalized treatment strategies and potentially more efficient therapies. As per Xtalks in May 2023, there were 452,604 registered clinical studies on ClinicalTrials.gov, with 64,838 actively seeking participants - a significant increase from 2021's 365,000 registered trials. This surge in clinical trials actively contributes to the burgeoning migraine treatment market.
Product innovations are a prominent trend gaining traction in the migraine treatment market. Leading companies in the sector are introducing novel solutions, such as liquid formulations, to maintain their competitive edge. For example, in January 2022, BioDelivery Sciences International (BDSI), a US-based pharmaceutical firm, launched Elyxyb (celecoxib oral solution), designed for the acute treatment of migraines in adults, regardless of whether they experience aura. This liquid formulation facilitates rapid absorption in the small intestine, resulting in quicker relief compared to conventional tablets. This innovation is particularly advantageous for migraine sufferers who experience nausea or vomiting, as it eliminates the waiting time for a pill to dissolve. As the first and only FDA-approved ready-to-use oral solution for migraines, Elyxyb offers a more tolerable and efficient treatment option for managing the sudden, intense pain associated with migraines.
Major players in the migraine treatment market prioritize product approvals, such as the zavzpret (zavegepant) migraine nasal spray, to bolster market revenues. Zavzpret, a calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray, targets the acute management of adult migraines. Notably, Pfizer Inc. received FDA approval for zavzpret (zavegepant) in March 2023. This nasal spray offers immediate relief for adult migraine attacks, aiming to provide pain relief with a single spray. The FDA's endorsement marks a significant milestone for migraine sufferers seeking alternatives to oral medications for prompt pain relief.
In May 2022, Pfizer Inc., a prominent biopharmaceutical company based in the US, successfully completed the acquisition of Biohaven Pharmaceutical Holding Company Ltd. for an estimated $11.6 billion. This strategic acquisition positions Pfizer to further its commitment in providing effective treatments for individuals worldwide afflicted by migraines. Biohaven Pharmaceutical Holding Company Ltd., also based in the US, possesses a diverse product portfolio focused on addressing neuropsychiatric diseases and neurological disorders.
Major companies operating in the migraine treatment market are Pfizer Inc., Eli Lilly and Company, Amgen Inc., GlaxoSmithKline PLC, Novartis AG, Bayer AG, Allergan PLC, Abbott Laboratories, Allodynic Therapeutics LLC, AOBiome LLC, AstraZeneca PLC, Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, Dr. Reddy's Laboratories Limited, Impel Pharmaceuticals Inc., AbbVie Inc., Alder BioPharmaceuticals Inc., Astellas Pharma Inc., Biohaven Pharmaceutical Holding Company Ltd., Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Endo International PLC, Impax Laboratories Inc., Johnson & Johnson Inc., Lannett Company Inc., Lupin Limited, Merck & Co. Inc., Mylan N.V.
North America was the largest region in the migraine treatment market in 2024. The regions covered in the migraine treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the migraine treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Migraines, a neurological condition, are characterized by severe headaches typically felt on one side of the brain. These pulsating headaches are the primary symptom of this condition. Migraine treatment aims to alleviate these intense and often debilitating headaches by targeting the brain's pain pathways. By effectively blocking these pathways, the treatment can halt future migraine attacks and alleviate associated symptoms.
Different types of migraine treatments cater to varying migraine presentations. Episodic migraine treatment addresses instances where individuals experience headaches for 0-14 days per month. This form of treatment encompasses various acute options tailored specifically for episodic migraines. Available treatments include acute/abortive methods, preventive/prophylactic approaches, as well as non-pharmacological therapies and devices. These treatments find applications across diverse settings, including hospitals, clinics, homecare, and other end-user environments.
The migraine treatment market research report is one of a series of new reports that provides migraine treatment market statistics, including migraine treatment industry global market size, regional shares, competitors with a migraine treatment market share, detailed migraine treatment market segments, market trends and opportunities, and any further data you may need to thrive in the migraine treatment industry. This migraine treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The migraine treatment market includes revenues earned by entities by providing branded and generic migraine treatment services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Migraine Treatment Market Characteristics3. Migraine Treatment Market Trends and Strategies4. Migraine Treatment Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market32. Global Migraine Treatment Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Migraine Treatment Market34. Recent Developments in the Migraine Treatment Market
5. Global Migraine Treatment Growth Analysis and Strategic Analysis Framework
6. Migraine Treatment Market Segmentation
7. Migraine Treatment Market Regional and Country Analysis
8. Asia-Pacific Migraine Treatment Market
9. China Migraine Treatment Market
10. India Migraine Treatment Market
11. Japan Migraine Treatment Market
12. Australia Migraine Treatment Market
13. Indonesia Migraine Treatment Market
14. South Korea Migraine Treatment Market
15. Western Europe Migraine Treatment Market
16. UK Migraine Treatment Market
17. Germany Migraine Treatment Market
18. France Migraine Treatment Market
19. Italy Migraine Treatment Market
20. Spain Migraine Treatment Market
21. Eastern Europe Migraine Treatment Market
22. Russia Migraine Treatment Market
23. North America Migraine Treatment Market
24. USA Migraine Treatment Market
25. Canada Migraine Treatment Market
26. South America Migraine Treatment Market
27. Brazil Migraine Treatment Market
28. Middle East Migraine Treatment Market
29. Africa Migraine Treatment Market
30. Migraine Treatment Market Competitive Landscape and Company Profiles
31. Migraine Treatment Market Other Major and Innovative Companies
35. Migraine Treatment Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Migraine Treatment Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on migraine treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for migraine treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The migraine treatment market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Types: Episodic; Migraine With Aura; Chronic; Other Types2) by Treatment: Acute or Abortive Treatment; Preventive or prophylactic Treatment; Non-Pharmacological Therapies and Devices
3) by End-User: Hospitals; Clinics; Homecare; Other End-users
Subsegments:
1) by Episodic: Frequent Episodic Migraine; Infrequent Episodic Migraine2) by Migraine With Aura: Visual Aura; Sensory Aura; Speech or Language Aura
3) by Chronic: Chronic Migraine Without Aura; Chronic Migraine With Aura
4) by Other Types: Hemiplegic Migraine; Retinal Migraine; Menstrual Migraine; Other Specific Types
Key Companies Mentioned: Pfizer Inc.; Eli Lilly and Company; Amgen Inc.; GlaxoSmithKline PLC; Novartis AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
Some of the major companies featured in this Migraine Treatment market report include:- Pfizer Inc.
- Eli Lilly and Company
- Amgen Inc.
- GlaxoSmithKline PLC
- Novartis AG
- Bayer AG
- Allergan PLC
- Abbott Laboratories
- Allodynic Therapeutics LLC
- AOBiome LLC
- AstraZeneca PLC
- Bausch Health Companies Inc.
- Boehringer Ingelheim International GmbH
- Dr. Reddy's Laboratories Limited
- Impel Pharmaceuticals Inc.
- AbbVie Inc.
- Alder BioPharmaceuticals Inc.
- Astellas Pharma Inc.
- Biohaven Pharmaceutical Holding Company Ltd.
- Bristol-Myers Squibb Company
- Daiichi Sankyo Company Limited
- Eisai Co. Ltd.
- Endo International PLC
- Impax Laboratories Inc.
- Johnson & Johnson Inc.
- Lannett Company Inc.
- Lupin Limited
- Merck & Co. Inc.
- Mylan N.V.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | February 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 3.48 Billion |
| Forecasted Market Value ( USD | $ 5.32 Billion |
| Compound Annual Growth Rate | 11.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 30 |
